对于罕见的难治性尿路癌，首个免手术治疗方案需要复杂的临床方案

BANNOCKBURN, Ill., May 21, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, has been selected by UroGen Pharma (NASDAQ: URGN) as a preferred national pharmacy provider to prepare and deliver a first-of-its-kind cancer treatment, Jelmyto™ (mitomycin) for pyelocalyceal solution.

新制剂为治疗成人低度上尿路癌 (LG-UTUC) 提供了一种新的方法，用一种随着温度变化而改变形态的药物直接靶向肿瘤，并且必须在制备后八小时内由医生提供。为了确保药物在规定的时间内按照产品标签要求和药房标准进行制备、运输并提供给患者，Option Care Health 与 UroGen 合作，创建了一个创新的药房解决方案，通过其遍布全国的无菌配药药房和分销网络来支持 Jelmyto。

Jelmyto 于 2020 年 4 月 15 日获得美国食品药品监督管理局的批准，是使用 UroGen 专有的 RTGel™ 缓释技术由丝裂霉素（一种成熟的化学疗法）和无菌水凝胶组成的一流疗法。它的设计目的是使泌尿道组织长时间暴露于丝裂霉素，从而通过非手术、保肾的方法促进对这些罕见且难以治疗的癌性肿瘤的治疗。

Jelmyto 必须在符合 USP 800 标准的药房中制备，这些药房采用更高的质量和安全标准，除了配药室外，还必须有更多的能力和专业知识来处理细胞毒性药物成分。Option Care Health 的全国 USP 800 药房网络将根据患者的特定 Jelmyto 处方制备配方，并在规定的时间内按照 Jelmyto 药房说明书的严格标准将其交付给泌尿科医生。  

“Option Care Health 在符合 USP 800 标准的药房网络中的基础设施和配药能力是无与伦比的，这使我们能够与 UroGen 公司合作提供全面的服务。”Option Care Health 公司总裁兼首席执行官 John C. Rademacher 说道。“每天，Option Care Health 都会确保成千上万的患者安全、及时地接受所需的治疗。我们在临床基础设施方面进行的投资使我们能够与 UroGen 合作，提供这种创新的新疗法。”

“UroGen 正在通过新型的非手术治疗替代方案（如 Jelmyto）挑战护理标准，这利用了我们在特种癌症和泌尿系统疾病方面的创新技术和专业知识，”UroGen 总裁兼首席执行官 Liz Barrett 说道。“Jelmyto 需要复杂的制备和及时的交付，而 Option Care Health 提供了我们要求合作伙伴所具备的全国规模、经验深度、专业知识和对质量的承诺，以确保患者及时安全地接受这种重要的新疗法。”

LG-UTUC 是一种罕见的癌症，发病于上尿路、输尿管和肾脏的内膜。每年约有 6,000 至 7,000 名美国患者被诊断为新发性或复发性 LG-UTUC。由于泌尿系统解剖结构复杂，治疗难度大。目前的标准护理包括多种手术，通常是根治性肾输尿管切除术，包括切除肾盂、肾脏、输尿管和膀胱袖带。

About Option Care Health

Option Care Health 是全美最大的家庭和备选站点输液服务的独立提供商。我们拥有 5,000 多名团队成员，其中包括约 2,900 名临床医生，我们在工作中饱含同情心，致力于提高所有 50 个州的急性和慢性病症患者的护理标准。通过我们的临床领导能力、专业知识和全国规模，Option Care Health 正在为患者、客户和员工重新构筑输液护理体验。要了解更多信息，请访问我们的网站 OptionCareHealth.com。

关于 UroGen Pharma Ltd.
UroGen 是一家生物制药公司，致力于打造治疗特种癌症和泌尿系统疾病的新型解决方案，因为患者值得拥有更好的选择。UroGen 开发了 RTGel™ 逆热水凝胶，这是一种基于水凝胶的专有缓释平台技术，有可能改善现有药物的治疗情况。UroGen 的持续释放技术旨在使尿路组织暴露在药物中的时间更长，从而使局部治疗成为潜在的更有效的治疗选择。UroGen 获得批准的肾盂积水溶液 Jelmyto™ （丝裂霉素）和膀胱内溶液的 UGN-102（丝裂霉素）管道治疗旨在通过非手术方式消融肿瘤并治疗多种形式的非肌肉浸润性尿路上皮癌，包括低度恶性上尿路尿路上皮癌和低度非肌肉浸润性膀胱癌。UroGen 的总部位于新泽西州普林斯顿市，在以色列设有业务部门。访问 www.urogen.com 了解更多信息或在 Twitter 上关注我们 @UroGenPharma。

前瞻性声明 – 安全港

本新闻稿可能包含 1995 年《美国私人证券诉讼改革法案》安全港条款所定义的“前瞻性声明”。前瞻性声明可以用诸如“预计”、“打算”、“计划”、“相信”、“项目”、“估计”、“预期”、“可能”、“应该”、“将要”以及对未来时期的类似提法来识别。前瞻性声明的例子包括但不限于，我们可能就未来收入、未来收益、监管发展、市场发展、新产品和增长战略、整合活动以及上述任何一项对我们未来经营业绩或财务状况的影响所作的陈述。

前瞻性声明既不是历史事实，也不是对未来业绩的保证。相反，它们只是基于我们当前对公司业务的未来、未来计划和战略、预测、预期事件和趋势、经济以及其他未来条件的信念、期望和假设。由于前瞻性声明与未来相关，因此它们受到固有的不确定性、风险和情况变化的影响，这些情况难以预测，其中许多是我们无法控制的情况。我们的实际结果和财务状况可能会与前瞻性声明中的内容存在重大差异。可能导致我们的实际结果和财务状况与前瞻性声明中的陈述存在重大差异的重要因素包括但不限于：(i) 适用于我们业务模式的法律和法规的变更；(ii) 市场状况以及对我们服务和产品的接受度的变化； (iii) 诉讼结果；(iv) 一家或多家主要支付方的损失； (v) 新冠疫情的传播和影响。有关可能影响我们实际结果的风险因素的详细讨论，请参阅美国证券交易委员会 (SEC) 报告中确定的风险因素，包括但不限于我们向 SEC 提交的 10-K 报表年度报告和 10-Q 报表季度报告。

我们在本新闻稿中所作的任何前瞻性声明仅基于我们当前可获得的信息，并且仅以发表之日为准。无论是书面形式还是口头形式，不管是由于新的信息、未来的发展还是其他原因，我们均不承担公开更新任何前瞻性声明的义务。

Ensuring Patient Safety and Continuity of Care is Key During COVID-19 Public Health Crisis as Hospitals Face Unprecedented Challenges

BANNOCKBURN, Ill., April 22, 2020 –  Regence and Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH) today announced an expanded partnership to ease access to care and provide additional options for high-risk patients who rely on infusion therapy. This collaboration enables Regence Health Plan members who currently receive their infusion therapy services in a hospital outpatient setting the ability to transition care to their home or an Option Care Health Infusion Suite.

Regence is committed to helping ease the burden on hospitals during the COVID-19 pandemic and ensuring its members and their families have the clinical care support they need, provided in the comfort, convenience and safety of a preferred location. Regence is a family of health plans in Oregon, Idaho, Utah and select counties in Washington, each an independent licensee of the Blue Cross and Blue Shield Association dedicated to making healthcare better, simpler and more affordable.

“Ensuring our members have convenient access to care in a safe and affordable setting is our top priority,” said Kerry Bendel, Regence’s Chief Pharmacy Officer. “Option Care Health’s 40-years of experience focused solely on infusion therapy makes them the right partner to help protect the health and safety of our members, their families and our community during the unprecedented challenges created by the COVID-19 crisis.”

The partnership – which builds on Regence’s existing Site of Care program – helps address changing needs during the COVID-19 pandemic, allowing for greater flexibility for hospitals, physicians and patients who rely on infusion therapies for a wide variety of acute and chronic needs, from nutrition support and immune disorders to infections and neurologic conditions.

“Infusion provided safely and effectively at home or an infusion suite is more vital to our nation’s health system and patients than ever before,” said John C. Rademacher, President and Chief Executive Officer of Option Care Health. “As we face this public health crisis, it is critical that we work together to continue delivering trusted clinical care that expands the overall capacity of our healthcare system.”

Option Care Health 遵循美国疾病控制和预防中心（CDC）的严格指导方针，以确保患者和工作人员的安全。这些措施包括对工作人员进行全面培训，在家中和输液室执行严格的感染控制规定，对工作人员和患者进行新冠肺炎症状筛查，针对病毒情况的持续更新和教育，以及使用个人防护装备（PPE）。员工可以 24 小时拨打 Option Care Health 新冠肺炎热线，咨询有关其个人健康或患者健康的问题。

Care managers and clinicians will contact high-risk Regence members to ensure they know about the option to receive infusion therapy care in an alternate setting. Option Care Health clinical teams will coordinate transitions of care and customize treatment plans to suit the specific needs of each patient, with an assigned nurse and pharmacist to monitor treatment. Experienced clinicians and nurses are available 24 hours a day, seven days a week, 365 days a year to answer questions and provide support for patients, families and providers.

For more information on the Option Care Health and Regence response to the COVID-19 pandemic, visit optioncarehealth.com/coronavirus and regence.com/member/health-lifestyle/coronavirus-covid-19.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is re-imagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at OptionCareHealth.com.

About Regence

Regence serves approximately 3.1 million members through Regence BlueShield of Idaho, Regence BlueCross BlueShield of Oregon, Regence BlueCross BlueShield of Utah and Regence BlueShield (select counties in Washington). Each health plan is a nonprofit independent licensee of the Blue Cross and Blue Shield Association. Regence is part of a family of companies dedicated to transforming healthcare by delivering innovative products and services that change the way consumers nationwide experience healthcare. For more information, please visit Regence.com.

输液护理提供者的临床专业知识和全国规模可确保在低风险环境下提供高质量的护理

BANNOCKBURN, Ill., April 14, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, is on the frontlines of the COVID-19 pandemic, working in collaboration with our nation’s hospitals and their clinical teams to ensure patients continue to receive vital care. Option Care Health provides essential infusion services that enable patients to transition home from the hospital sooner, freeing up beds for critically ill COVID-19 patients.

Serving patients in all 50 states, Option Care Health is easing the burden on strained health systems in critical markets. Physicians and patients rely on infusion therapies for a wide variety of acute and chronic needs, from nutrition support and immune disorders to infections and neurologic conditions. Option Care Health is a critical part of the pandemic response, developing unique solutions that safely transition patients requiring infusion therapy out of the hospital – flexing capacity by deploying and shifting resources where the need is the greatest and utilizing the more than 125 infusion sites it operates across the country.

“We are fighting this pandemic side by side with our health system partners, fully prepared and able to support the needs of their patients who can transition home to continue their therapy. Whether they are in pre-plan preparation or already at surge capacity in a pandemic hotspot, our team is responding quickly and effectively to meet their needs,” said Harriet Booker, Chief Operating Officer of Option Care Health. “We’re not missing a beat. If our partners need us to accommodate a 10 p.m. bedside discharge for a patient on IV antibiotics medication, transfer a rheumatoid arthritis patient from a hospital-based ambulatory care center or virtually discharge an immunocompromised patient to reduce the risk of COVID-19 transmission, we’re where they need us to be.”

Option Care Health 全面的网络和业务连续性计划确保了其在全国范围内为患者提供持续可靠的输液药房和护理服务的能力。这种实时敏捷性采用了加班、远程人员轮换和延长药房工作时间的方式来配制和施用重要药物。此外，Option Care Health 能够将临床资源重新部署到最需要的城市。

Option Care Health has implemented rigorous protocols to ensure the safety of patients and staff working directly with its infectious disease experts and following Centers for Disease Control and Prevention (CDC) guidelines. These measures include comprehensive training of employees, strict protocols for infection control at home and infusion suites, screening of staff and patients for COVID-19 symptoms, ongoing virus-specific updates and education and the use of personal protection equipment (PPE). Staff members can call an Option Care Health COVID-19 hotline 24/7 to address questions regarding their health or a patient’s health. 

“Infusion at home or an infusion suite is a safe and effective care setting that is even more vital during times of national emergency, such as the current COVID-19 crisis,” said John C. Rademacher, President and Chief Executive Officer of Option Care Health. “Our highly skilled team of healthcare professionals provide infusion services that deliver hope to patients and physicians by easing the burden on hospital inpatient census, while lowering the patient’s risk and ensuring they receive excellent care after they are discharged.”

Option Care Health’s clinical team, consisting of 2,900 nurses, dietitians and pharmacists, annually care for more than 220,000 patients of all ages. The Option Care Health clinical team elevates the infusion therapy experience through customized care plans specific to every patient. Experienced clinicians and nurses are available 24 hours a day, seven days a week, 365 days a year to answer questions and provide support for patients, families and providers.

For more information on Option Care Health’s response to the COVID-19 pandemic, visit  optioncarehealth.com/coronavirus.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is re-imagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at OptionCareHealth.com.

Infusion therapy devices have been in the news lately—due, in no small part, to concerns surrounding their hackability.

Below, two individuals representing the infusion therapy manufacturing sector Rob Suárez, vice president, chief information security officer at BD, and Matthew Hutchings, ICU Medical’s vice president, global marketing and innovation, infusion systems—join Alyssa Moy, director, adoption and integration at home and alternate treatment site infusion therapy services provider Option Care, to discuss what’s new in infusion therapy and how HTM professionals are integral in keeping infusion devices secure. Don’t miss out.

Click the link below to read the full article published in 24×7 Magazine. 

INSIDE THE INFUSION THERAPY DEVICE SECTOR

Largest Independent Home and Alternate Site Infusion Provider Establishes the Standard of Care Across the United States Through Its Clinical Leadership and Technology-Enabled 以患者为中心的模式

伊利诺伊州班诺克本和丹佛，2019 年 8 月 7 日讯 —  Option Care Enterprises, Inc. (“Option Care”) 和 BioScrip, Inc. (“BioScrip”) 今天宣布成功完成合并，此前交易的完成条件已得到满足，包括 BioScrip 股东的批准和获得所有必要的监管批准。

The newly combined company, Option Care Health, Inc. (“Option Care Health” or the “Company”), emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.

Option Care Health 首席执行官 John Rademacher表示：“今天标志着令人振奋的新篇章的开始，因为我们将两个实力雄厚的组织、有着悠久历史的市场领导者联合起来。此次合并使我们能够重新构想输液护理体验，在全国范围内以较低的成本充分释放出高品质护理的潜力。我们现在是唯一一家专注于为全国患者提供全方位输液治疗的独立提供者。我们深厚的临床专业知识、广泛的疗法组合以及增强的财务状况使我们有能力提供卓越的疗效，并为患者护理树立标准。”

Option Care Health 将继续专注于：

• Patient-Centered Care Model, providing deeply personalized care to patients in all 50 states, supported by the broadest commercial and clinical coverage with our unique product offering.
• Clinical and Market Leadership, leveraging our best-in-class clinical team to consistently raise quality standards and patient outcomes while collaborating with health systems, payers and manufacturers to broaden our therapy portfolio and clinical reach.
• 在制定输液服务行业标准的同时，投资于人力、技术和运营以推动盈利增长。

Daniel E. Greenleaf, former Chief Executive Officer of BioScrip, commented, “I’m proud of the BioScrip team and the care that we delivered every day to patients who trusted us to provide extraordinary care. This new enterprise combines two independent market leaders and enables the organization to truly redefine infusion therapy in the alternate site setting. With a significantly improved capital structure and financial profile, I’m confident Option Care Health will continue to build upon the momentum of BioScrip and Option Care.”

Option Care Health 的总部将设在伊利诺伊州班诺克本，由 Rademacher 担任首席执行官，Mike Shapiro 担任首席财务官。Baxter International Inc. 前董事长兼首席执行官 Harry Kraemer 将担任 Option Care Health 董事会主席。

Advisors

In connection with the transaction, Jefferies LLC and Moelis & Company LLC acted as joint financial advisors to BioScrip, and Gibson, Dunn & Crutcher LLP served as legal advisor. Goldman Sachs & Co. LLC and BofA Merrill Lynch acted as financial advisors and Kirkland & Ellis LLP acted as legal advisor to Option Care.

前瞻性声明

This communication contains “forward-looking statements ” (as defined in the Private Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of Option Care Health. All statements other than statements of historical facts are forward-looking statements. In addition, words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words, and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements.

Forward-looking statements relating to Option Care Health include, but are not limited to: statements about the benefits of the combined company, including future financial and operating results; expected synergies; Option Care Health’s plans, objectives, expectations and intentions; and other statements relating to the merger that are not historical facts. Forward-looking statements are based on information currently available to BioScrip and Option Care and involve estimates, expectations and projections.

敬请投资者注意，所有此类前瞻性声明均会受到风险和不确定性（已知和未知）的影响，并且许多因素可能导致实际事件或结果与此类前瞻性声明所表明的内容发生重大差异。关于 BioScrip 和 Option Care 的合并，这些因素可能包括但不限于：(i) 与合并相关的大量债务可能对 Option Care Health 运营合并后业务的能力产生影响，(ii) 与 BioScrip 和 Option Care 的业务、解决方案和员工整合到合并后的公司有关的风险，以及预期的协同效应和合并后的其他利益（包括成本节约）无法实现或无法在预期时间内实现的可能性，(iii) Option Care Health 作为纳斯达克意义上的“受控公司”的地位，包括 Option Care Health 对某些公司治理标准的豁免的依赖，以及合并前持有人现在对 Option Care Health 的影响力大大降低； (iv) 与合并后的业务以及合并后的公司所在行业相关的风险。

这些风险和不确定性以及其他风险和不确定性在 BioScrip 于 2019 年 6 月 26 日向 SEC 提交的最终委托书声明和 Option Care Health 随后向 SEC 提交的文件中进行了更充分的讨论。虽然此处和 Option Care Health 公开文件中列出的风险因素列表具有代表性，但此类列表不应被视为所有潜在风险和不确定性的完整陈述。其中许多风险、不确定性和假设超出了 BioScrip 和 Option Care 的控制或预测能力。由于存在这些风险、不确定性和假设，因此您不应过度依赖这些前瞻性声明。此外，前瞻性声明仅以作出声明之日各方目前可获得的信息为依据，BioScrip 和 Option Care 均不承担公开更新或修改任何前瞻性声明以反映本通讯日期后可能出现的事件或情况的义务。

关于 Option Care Health

Option Care Health, Inc. (Option Care Health)（纳斯达克：BIOS）是美国最大的独立家庭和备选站点输液服务提供商。我们拥有 6,000 多名团队成员，其中包括 2,900 名临床医生，我们体恤工作，致力于提高所有 50 个州的急性和慢性病症患者的护理标准。通过我们的临床领导能力、专业知识和全国规模，Option Care Health 正在为患者、客户和员工重新构想输液护理体验。要了解更多信息，请访问我们的网站 OptionCareHealth.com。

For Media Inquiries:

Rachel Bowen, PCI

312.558.1770

RBowen@pcipr.com

For Investor Inquiries:

Mike Shapiro，首席财务官

Option Care Health

312.940.2538

Investor.relations@optioncare.com

全美领先的家庭和备选治疗站点输液服务提供者 Option Care Enterprises, Inc. 今天庆祝其位于亚特兰大市的全新先进的护理管理中心 (CMC) 开业。剪彩活动和开放日的参与者有机会参观新中心，该中心拥有最先进的输液技术和设备，环境温馨舒适。

CMC 为依赖复杂输液治疗的患者提供抗感染、临床营养支持、免疫球蛋白治疗以及慢性炎症和出血性疾病等方面的服务，将为约 1,000 名患者提供居家或门诊输液室 (AIS) 的护理。新中心不仅扩大了 Option Care 为亚特兰大地区的更多患者提供重要护理服务的能力，其全方位服务的药房和无菌配药室达到并超出了现行法规标准。

CMC 通过以下方式提供便捷的护理服务和卓越的临床支持：

• 患者的全方位服务输液药房和临床管理，包括药物的配制和分配，以确保每位患者在适当的监测下获得正确剂量的正确药物，以及临床医生全天候的电话支持，以解答患者/照料者和提供者的问题。
• 门诊输液室配备三张输液椅，提供私人房间，由经过输液治疗专门培训、技艺精湛的护士向患者施行治疗。
• 协助病人登记，服务时间灵活（包括晚上和周末），现场免费停车，交通便利。

“这家位于佐治亚州桃树角市的新 Option Care CMC 为患者提供了另一种治疗选择，无论是患者希望在全新先进的设施中接受输液服务，还是在自己舒适的家中接受输液服务。该设计不仅美观，而且是按照无菌配药设施的黄金标准建造而成。”亚特兰大市医师医学博士 Anson Kwame Wurapa 最近访问 CMC 时表示。

许多患者更愿意在 Option Care 临床护理团队的支持下在自己舒适的家中接受输液。然而，由于各种因素，家庭输液可能并不适合所有人，这些因素包括个人倾向于离家接受治疗、缺乏合适的家庭治疗环境、合并症需要全科护理团队的近距离服务，以及医疗保险承保范围的限制。Option Care 亚特兰大市 CMC 的设备可帮助该地区的所有输液患者在家中或在门诊输液室接受治疗。

“这家新的 CMC 是 Option Care 为患者提供的一流服务。我们知道这些关键疗法使患者能够享受活力和生活质量，我们很高兴能够为亚特兰大地区的更多患者提供这种治疗。” Option Care 首席执行官 John Rademacher 说道。“这家新的 CMC 代表了我们的承诺，即通过最好的临床医生和设施提供卓越的临床护理。”

路易斯安那州护理管理中心将会配备 Option Care 先进的技术辅助式数据驱动服务和项目，以提供优质的疗效。

关于 Option Care

Option Care Enterprises, Inc. (Option Care) is the nation’s largest and most trusted provider of home and alternate treatment site infusion services. Holding accreditations from industry quality organizations ACHC, PCAB, ASHP and URAC,[*]Accreditation Commission for Health Care (ACHC), Pharmacy Compounding Accreditation Board (PCAB), American Society of Health-System Pharmacists (ASHP) and URAC the company draws on over 40 years of clinical care experience to offer patient-centered therapy management.

Option Care 的标志性输液疗法+服务包括输液药物的临床管理、护理支持和护理协调。Option Care 由 1,700 多名临床从业人员（包括药剂师、护士和营养师）组成的多学科团队能够为美国各地需要接受复杂和慢性病治疗的几乎所有患者提供家庭输液服务覆盖。有关详情请访问 www.OptionCareHealth.com。

For the past 40 years, Option Care has been dedicated to providing quality infusion therapy that makes a positive difference in each patient’s life. Prior to this, patients requiring nutrition support could only receive their infusions at a hospital. When two pharmacists in Chico, California heard about a 19-year-old man enduring 10 hours of nutrition therapy daily, they proposed delivering his treatment in the home, enabling him to lead a more normal life.

As we celebrate our 40^th anniversary, we sat down with Michael Prime, one of Option Care’s founding pharmacists to discuss our history and how serving a single car accident patient, along with his partner, Mitchell Hoggard, launched one of the nation’s leading infusion companies.

OC: Tell me, in your own words, how you discovered the need for home infusion.

MP: There was a young man involved in an automobile accident and through the course of multiple surgeries, he lost most of his bowel, leaving him unable to absorb food orally. My partner was a pharmacist at a hospital in Red Bluff, just north of Chico. This young man was receiving TPN solution there; he required four liters a day, every day — it was a 10-hour infusion. This was just one of those things that (Hoggard) came to me saying that there was this man, sitting in our hospital, getting infusions daily and I think we can provide this in the home.

I didn’t know much about it at the time but thought to myself, why couldn’t we? I was ready to take on the challenge. Shortly afterwards, we spoke with the prescribing physician, getting him to agree that we could provide therapy to the patient once we had the proper license. So we began that long process — (Hoggard) stayed working at the hospital and I happened to own a retail store in downtown Chico — we contacted the insurance agency, found a space for a clean room with a hood to prepare the solution and began taking the work out of the hands of the hospital.

Once that was set up, the patient was released from the hospital and we began delivering solution to his home. Although he was already trained on how to self-infuse, we realized the importance of hiring registered nurses to help support the influx of patients that were being referred to us following this young man’s successful transition to home infusion.

OC: When you and Mr. Hoggard launched the company 40 years ago, did you have any idea that it would become what it is today?

MP: Well, it really was just us doing it; there was no marketing involved. Our infusion treatment in the home started to spread by word of mouth. In fact, the first physician referred another patient of his to our care as well. Eventually, other doctor’s in town began sending us IV antibiotic patients and I had to sell my half of the retail store so I could focus on Option Care full-time.

My partner was the visionary for Option Care. He was the type of person that envisioned what things should look like in the future, whereas I was the one responsible for taking care of the patients. So while I truly never envisioned it growing into what it is today, I believe he operated under the assumption that we could eventually service patients across the country.

OC: It seems like that happened rather quickly because the need for this type of service was so large. When did you finally realize you needed to begin expanding the number of employees at Option Care?

MP: At the beginning, I was not only mixing the therapies in our clean room, but I was traveling to each patient’s home to teach them how to infuse and use their equipment. We started by hiring two nurses who helped support patient care outside of what I could do myself. I was spending about half my time on the road to patient’s homes and delivering their therapy. Often times, staying the night with patients because we were training them or their caregivers on how to infuse the drug, use the pump or change a dressing, which they were nervous to be doing on their own in the beginning, was normal for us.

I loved being able to truly care for our patients. I was able to provide comfort in their ability to safely administer the drug and training on how to keep themselves or their loved one safe. I never wanted to see that change.

Of course, as you continue to grow, some things do need to change. We started being approached by other pharmacists in northern California who had heard about us through word of mouth or listened to us speak at pharmacy conventions. We developed a licensing agreement with them to begin doing business with us. We’d prepare the solution, assist with billing and licensing as well as train them on how to care for the patients like we do. It was at this time that our attorney advised us to begin franchising in order to protect ourselves. This began our nationwide expansion.

OC: Once you began franchising and you took on a more corporate role, how were you able to continue to focus on the quality of patient care?

MP: I became the Corporate Franchise Relations-guy, flying around the country to visit each pharmacy and ensuring they were doing things our way. Through those travels, I was able to serve as a founding member of the National Home Infusion Association (NHIA), helping to set the standards for the infusion industry. I eventually served as the president of the organization giving me the ability to update and progress industry standards into the future.

It took me quite a while to get used to serving in a corporate role, to be honest. I feel like I’m a small guy from Chico, a pharmacist and then all of a sudden I was serving in this corporate, franchise public relations role, which was a big shift for me.

OC: Can you tell me how Option Care got its name?

MP: When we started in 1979, we were operating as CliniCare until we began expanding and tried to license our name. That’s when we discovered the name had already been registered by another organization and we couldn’t use it. One of our marketing people came up with the idea of Outpatient Parental Therapy Intravenous On-going Nutrition with Care on the end – O.P.T.I.O.N. Care — as a way to explain exactly what we were as a company.

We eventually changed the name to lose the acronym and just became Option Care in the early 1990’s. With these changes, our logo transformed throughout the years as well.

OC: Since we started with nutrition therapy, I think it’s an interesting fact that we recently became a Gold sponsor of the Oley Foundation. Did you have any involvement with them?

MP: Oh wow, I remember when Oley first started! We had some patients who were actively involved with Oley in the past. I’m glad to hear that Option Care is still staying with its roots after all these years. We were never involved with them during my time at the company so I’m really glad to hear of your commitment to the Oley Foundation and their mission.

Learn more about our nutrition support services and our partnership with the Oley Foundation.

Creates a Leading Independent Provider of Home and Alternate Site Infusion Services with Deep Clinical Expertise and Broad Therapy Portfolio

Enhanced Scale and Improved Financial Profile Expected to Enable Growth in Attractive and Growing Segment of U.S. Healthcare Market

BioScrip to Issue New Shares to Option Care’s Shareholder, Which Will Own Approximately 80% of Combined Company on Fully Diluted Basis

Combined Company Will Remain Focused on Delivering Favorable Outcomes for Patients, Payors and Providers

DENVER and BANNOCKBURN, Ill., March 15, 2019 —  BioScrip, Inc. (NASDAQ: BIOS) (“BioScrip”) and Option Care Enterprises, Inc. (“Option Care”), the nation’s largest independent providers of home and alternate treatment site infusion therapy services, today announced that they have entered into a definitive merger agreement. The combination is expected to create a leading independent provider with the national reach, comprehensive therapy offering and financial capacity to succeed in the attractive and growing home and alternate site infusion services segment of the $100 billion U.S. infusion market.

根据合并协议的条款，BioScrip 将向 Option Care 的股东发行新股，该股票由 Madison Dearborn Partners, LLC ( “MDP”) 和 Walgreens Boots Alliance, Inc. （纳斯达克：WBA）(“WBA”) 所拥有，以全股票交易方式进行。交易完成后，MDP 基金和 WBA 将在全面摊薄的基础上实益拥有合并后上市公司约 80% 的股权，而 BioScrip 现有股东将持有剩余的股权。合并后公司的普通股将继续在纳斯达克全球市场上市。该交易已获得 BioScrip 和 Option Care 董事会的一致批准。

The combined company will be led by Option Care Chief Executive Officer John Rademacher and Option Care Chief Financial Officer Mike Shapiro and will incorporate the best talent, processes and systems from both Option Care and BioScrip. It also will have a leading, independent clinical platform for delivering high-quality infusion therapy to more patients across the United States and providing superior outcomes for patients, payors and providers. BioScrip President and Chief Executive Officer Daniel E. Greenleaf will remain active in the combined company as a special advisor to its Board of Directors.

Daniel E. Greenleaf, President and Chief Executive Officer of BioScrip, commented, “This is a compelling and complementary fit of two leading players in the U.S. infusion market. Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States. Our expanded reach and broader array of offerings provide a key competitive advantage at a time when the demand for home and alternate site infusion services continues to grow. The BioScrip Board and I believe our shareholders will have the compelling opportunity to participate alongside Option Care’s experienced and seasoned shareholders in the long-term potential and value creation opportunities of the combined company.”

John Rademacher, Chief Executive Officer at Option Care, said, “This transaction brings together two organizations and thousands of employees dedicated to creating a best in class experience for our patients and their families. Our goal is to constantly improve the delivery of life-saving therapies and comprehensive care management to the patients we have the privilege of serving. At the center of both organizations is deep clinical expertise and a passion to deliver extraordinary care. We believe combining our unique assets and leading product portfolios will create a powerful, independent platform that will enable delivery of high-quality, cost effective solutions to providers across the country and help facilitate the introduction of innovative new therapies to the marketplace. As an independent provider, we will retain the unique ability to deliver high-quality infusion therapy in the patient-preferred and safer setting of the home or an alternate site to every commercial and governmental payor.

“I am honored to lead the combined company and work with BioScrip’s and Option Care’s talented and dedicated employees, who share a strong commitment to delivering exemplary care that makes a positive difference in people’s lives. I look forward to harnessing the strengths of both of our organizations and industry-leading teams to capitalize on the many growth opportunities this combination creates to drive long-term value for all stakeholders.”

Expected Benefits of the Transaction

• Improved, Cost-Effective Patient Care. Utilizing clinical monitoring and reporting, the combined company’s more than 2,900 skilled clinicians (pharmacists, pharmacy technicians, nurses and dieticians) will develop personalized care plans for patients and be able to provide ongoing quality care in support of complex therapy regimens. With a best-in-class platform that is national in scope, the combined company will also be positioned as the partner of choice for pharmaceutical manufacturers seeking innovative distribution channels and patient support models to access the market. Together, BioScrip and Option Care will cover 96% of the U.S. population, with facilities in 46 states and the ability to dispense and serve patients in all 50 states.
• Enhanced Scale and Therapy Offerings. The combined company will merge BioScrip’s and Option Care’s complementary portfolios and provide products that are currently only available to one of the two businesses, such as Option Care’s access to Cuvitru for the treatment of primary immunodeficiency and Nuzyra™ for the treatment of adults with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. The combined company’s expanded geographic coverage, continued independence, leading quality offerings and comprehensive clinical expertise will position it to be a preferred partner for payors, providers, biopharma manufacturers and patients. Furthermore, its enhanced scale will enable it to capture scale efficiencies and create additional vectors of growth through new product and service introductions.
• Powerful Growth Engine in Attractive Industry. Home and alternate site infusion, which currently accounts for approximately 12% of the $100 billion total U.S. infusion market, is estimated to grow approximately 5-7% per year due to attractive market dynamics, including the shift to value-based care that improves clinical outcomes and delivers better results for payors and providers as well. The combined company will have the financial capacity and flexibility, scale and clinical offering diversity to drive organic growth in chronic and acute therapies along with generating growth through operational efficiencies, improved performance in revenue cycle management and innovative new therapy introductions. The combination of BioScrip and Option Care will create a diversified business across payors, therapies and geographies in which no existing payor will account for more than 11% of net revenue.
• 令人信服的财务效益：该交易预计将推动有意义的运营和供应链效率，产生超过 6,000 万美元的净协同效应，预计将在交易结束后 24 个月内实现全面运行。这些预测的协同效应和合并后公司规模的扩大，以及 2018 年的预计收入超过 26 亿美元，有望实现顶线和底线增长。此外，BioScrip 和 Option Care 还获得了 Bank of America Merrill Lynch、Ares Management Corporation 下属基金和 Goldman Sachs Merchant Banking Division 的承诺融资，以对合并后的公司进行再融资和简化资本结构，预计合并后公司的短期资本期限不会到期，没有优先股，也没有财务维护契约。预计新的资本结构将为合并后的公司提供较低的预计合并后净杠杆率、较低的资本成本、大量额外的流动性和持续去杠杆化的路径。合并后的公司将奉行均衡的资本配置策略，继续投资于和提升患者体验，以及其人员和服务，以推动有机增长，同时管理其债务状况，并继续以严谨的方式去杠杆化。

Shareholders and Management Focused on Driving Value Creation

MDP, a leading private equity firm based in Chicago, has a long and successful history investing in health care companies and partnering with them to achieve growth and significant long-term value appreciation. MDP’s notable health care investments include Ikaria Inc., Sage Products, Sirona Dental Systems, Team Health and VWR International. Option Care, formerly Walgreens Infusion Services, has been an independent company since it was separated from WBA in 2015 in a joint investment partnership between MDP funds and WBA.

Timothy P. Sullivan, a Managing Director and Head of the MDP Health Care team and a Director of Option Care, said, “We believe this transaction provides significant shareholder value creation potential and we are excited to remain a major shareholder alongside Walgreens Boots Alliance in the combined company. John, Mike and the joint leadership team bring operational expertise and strong integration track records. Since separating from Walgreens, we have made significant investments in people, process, technology and facilities. This experience, combined with their commitment to patient-centric care, should drive meaningful and long-term shareholder value.”

Rademacher and Shapiro are seasoned health care professionals with significant operational expertise and public company experience. Rademacher has held various executive-level positions at leading public healthcare companies, including Cardinal Health where he served as President and General Manager for both the Ambulatory Care Division and the Nuclear and Pharmacy Services Divisions, and at Cigna Corporation where he served as President of CareAllies and Chief Operating Officer for the CIGNA Behavioral Health business. Shapiro served as the Senior Vice President and Chief Financial Officer for Catamaran Corporation, a publicly-traded pharmacy benefits manager, and led the successful process through which the company was sold to UnitedHealth Group. He also had a longstanding career with Baxter International, holding several financial positions across several businesses and corporate functions.

Rademacher has spearheaded Option Care’s Zenith 20/20 program, which changed the company’s operating model, implementing technology, operational design and facility upgrades throughout the organization. Under his leadership, Option Care has focused on providing high-quality care and improving delivery of services to patients, payors and manufacturers. The combined company, its employees and all stakeholders are expected to benefit from a leadership team focused on creating a culture that connects its clinical expertise and company success to patient outcomes.

In addition to Rademacher and Shapiro, the combined company’s leadership will draw from the experienced teams of both Option Care and BioScrip.

The transaction, which is expected to be completed in the second half of 2019, is subject to the satisfaction of customary closing conditions, including regulatory approvals and approval by BioScrip shareholders.

Conference Call, Webcast and Presentation

BioScrip 和 Option Care 将于美国东部时间 2019 年 3 月 15 日上午 9:00 召开电话会议，讨论交易事宜。电话拨入号码为 (877) 423-9820（美国免费电话）或 (201) 493-6749（国际电话）。电话会议的实时网络直播和相关演示材料可在 BioScrip 网站的“投资者”部分查看，网址为：www.bioscrip.com。

电话会议的在线重播可于电话会议结束后约两小时在 BioScrip 网站的“投资者关系”部分查看，网址为：www.bioscrip.com。

Advisors

In connection with the transaction, Jefferies LLC and Moelis & Company LLC are acting as joint financial advisors to BioScrip, and Gibson, Dunn & Crutcher LLP is serving as legal advisor. Goldman Sachs & Co. LLC and BofA Merrill Lynch are acting as financial advisors and Kirkland & Ellis LLP is acting as legal advisor to Option Care.

FORWARD LOOKING STATEMENTS
除历史信息外，本通讯还包含“前瞻性声明”（定义见 1995 年《美国私人证券诉讼改革法案》），其中涉及 BioScrip 和 Option Care 的未来事件或未来财务表现。除历史事实声明外，其他所有声明均为前瞻性声明。此外，诸如“预计”、“相信”、“考虑”、“继续”、“可能”、“估计”、“期望”、“打算”、“可以”、“计划”、“潜在”、“预测”、“项目”、“寻求”、“应该”、“目标”、“将”、“会”等词语或这些词语的否定词，以及在讨论未来计划、行动或事件时使用的类似内容的词语和术语，均可视为前瞻性声明。

Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the benefits of the proposed transaction between BioScrip and Option Care, including future financial and operating results; BioScrip’s and Option Cares plans, objectives, expectations and intentions; the expected timing of completion of the proposed transaction; and other statements relating to the acquisition that are not historical facts. Forward-looking statements are based on information currently available to BioScrip and Option Care and involve estimates, expectations and projections.

Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties (both known and unknown), and many factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed transaction between BioScrip and Option Care, these factors could include, but are not limited to: the risk that BioScrip or Option Care may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk that a condition to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction, which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; the effect of future regulatory or legislative actions on the companies or the industries in which they operate; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect; economic and foreign exchange rate volatility; and the other risks contained in BioScrip’s most recently filed Annual Report on Form 10-K.

其中许多风险、不确定性和假设超出了 BioScrip 的控制或预测能力。由于存在这些风险、不确定性和假设，因此您不应过度依赖这些前瞻性声明。此外，前瞻性声明仅以作出声明之日各方目前可获得的信息为依据，BioScrip 和 Option Care 均不承担公开更新或修改任何前瞻性声明以反映本通讯日期后可能出现的事件或情况的义务。本通讯中的任何内容均无意或不应解释为利润预测，也不应解释为意味着当前或任何未来财政年度或合并后公司的 BioScrip 每股收益一定会与历史上公布的 BioScrip 每股收益（如适用）相同或超过。

BioScrip 或 Option Care 均不保证 (1) BioScrip 或 Option Care 将实现其预期，或 (2) 在任何情况下，关于任何监管措施、行政诉讼、政府调查、诉讼、警告信、同意法令、成本削减、商业策略、收益或收入趋势或未来财务业绩等方面的任何结果或时间安排。所有后续有关 BioScrip、Option Care、拟议交易、合并后的公司或其他事项的书面和口头前瞻性声明，以及归因于 BioScrip 或 Option Care 或任何代表他们行事的人士的声明，均明确受上述警告性声明的全部限制。

ADDITIONAL INFORMATION AND WHERE TO FIND IT

BioScrip, Inc. （以下简称“BioScrip”或“公司”）将向美国证券交易委员会（以下简称“SEC”）提交与拟议交易有关的委托书。委托书将包含有关拟议交易及相关事项的重要信息。恳请并建议投资者和证券持有人阅读该委托书，因为其将包含重要信息。

本公司向 SEC 提交的委托书和其他相关材料以及任何其他文件可在 SEC 网站上免费获取，网址为：www.sec.gov。此外，证券持有人可通过邮件联系投资者关系部（地址：1600 Broadway, Suite 700, Denver, CO 80202，收件人：Investor Relations）、拨打电话 (720) 697-5200 ，或者访问公司网站上的“投资者关系”页面：https://investors.bioscrip.com。

PARTICIPANTS IN THE SOLICITATION

本公司及其董事和高管人员可被视为参与就上述事项向股东征集委托书。有关本公司董事和高管人员的信息，已在 2018 年 4 月 4 日提交给 SEC 的公司 2018 年年度股东大会附表 14A 的委托书中阐明。该文件可从上述来源免费获取。  

有关本公司董事和高管人员对公司证券中的所有权信息包含在公司向 SEC 提交的表格 3、4 和 5 中，这些表格可在 SEC 的网站上找到：www.sec.gov。有关征集委托书参与者的其他信息，以及参与者按所持证券或其他方式对直接和间接权益的描述，将包含在初步委托书和最终委托书以及其他相关材料中，这些材料将在可用时提交给 SEC。

About BioScrip, Inc.

BioScrip, Inc. is one of the largest independent national providers of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

关于 Option Care

Option Care Enterprises, Inc. (Option Care) 是全美领先和最值得信赖的家庭和备选站点输液服务提供者。本公司获得业内质量组织 ACHC、PCAB、ASHP 和 URAC 认证*，汲取了近 40 年的临床护理经验，提供以患者为中心的治疗管理。Option Care 的标志性输液服务包括输液药物的临床管理、护理支持和护理协调。Option Care 由 1,800 多名临床从业人员（包括药剂师、护士和营养师）组成的多学科团队能够为美国各地需要接受复杂和慢性病治疗的几乎所有患者提供输液服务覆盖。有关详情请访问 www.OptionCare.com。

ORLANDO, Fla., March 11, 2019 — New research by Option Care Enterprises, Inc. (“Option Care”), the nation’s leading provider of home and alternate site infusion therapy services, suggests the method of antibiotic intravenous (IV) administration can improve patient compliance while decreasing costs. The study[*]Wurdeman J, Decaminada G, Andrusko-Furphy K, et al. Comparison of compliance and comprehensive cost for various methods of administration of intravenous antibiotics in a home infusion setting. Poster presented at the National Home Infusion Association (NHIA) Annual Conference; March 9-13, 2019, Orlando, Fla. was presented today at the National Home Infusion Association (NHIA) Annual Conference and is a finalist for the “Outstanding Abstract Achievement Award.

The researchers analyzed patient compliance by comparing four techniques for antibiotic self-administration and determined ease of providing therapy was a significant factor. They concluded patients were significantly more likely to comply with therapy if they used the elastomeric pump or IV push than if they used the gravity/mini bag or electronic pump. Additionally, in many cases IV push and elastomeric pump are less costly.

“There’s a common perception that the gravity/mini bag is the least expensive method, but our research shows not only are IV push and elastomeric pump often more cost-effective, but patients find them easier to use, decreasing the likelihood that they will skip doses, which can lead to failed therapy and hospital readmission,” said Julie Wurdeman, PharmD, an Option Care infusion pharmacist and primary author of the study. “Our findings have implications for helping establish the most appropriate method of administration and underscore the value of collaboration among patients and the care team.”

The type of IV antibiotic therapy typically is chosen by the pharmacist in collaboration with the physician and determined by several factors including the medication, frequency of therapy (typically one to three times a day), rate of infusion as well as provider preference, patient lifestyle and age. The research suggests that patient compliance and cost should be factored into the equation.

Researchers studied treatment compliance in 688 Option Care home infusion patients who were treated between October 2017 and October 2018 and who missed one or more doses of IV antibiotics. They found the percentage of doses missed by technique was: 2.6 percent elastomeric pump, 2.7 percent IV push, 5 percent mini bag and 8.6 percent electronic pump.

There is a wide variation between methods in the cost of administration (factoring in equipment, compounding and patient education, but not medication), including a 209 percent difference between the least-expensive, IV push, and the most-expensive, electronic pump. The cost varies depending on the number of times per day and the rate at which the antibiotic is provided, as well as whether equipment can be reused and other factors.

In home antibiotic therapy, the patient infuses the medication through a catheter (placed by a nurse in a vein, usually in the hand or arm). The medication typically is administered one of four ways:

• IV push: The patient injects the medication via a syringe. This process is easy to learn, portable and fast.
• Elastomeric pump: The tennis ball-sized device comes pre-filled with the medication and self-squeezes it through tubing into a port the patient inserts into the catheter. This technique is easy to learn, precise and portable.
• Gravity/mini bag: The patient hangs the bag of medication on a pole and inserts the end of the tube into the catheter. The equipment involves set-up and is bulky, so it is not easily portable.
• Electronic pump: The patient connects the medication to the pump as well as the tube into the catheter and turns on the pump. The equipment involves set-up and is bulky, requiring the patient to carry the pump wherever he or she goes.

“While the type of antibiotic and rate of administration are the most important factors in determining the method of administration, in many cases there is flexibility,” said Wurdeman. “It’s important to consider all factors — including patient preference — which can help improve compliance and decrease costs.”

For its first Outstanding Abstract Achievement Award, the National Home Infusion Foundation chose abstracts that examine an innovative approach to clinical practice; identify a best practice or improve quality; are relevant to a current challenge, issue or question facing the home infusion industry; employ an effective study design/methodology to achieve results and have the ability to be expanded to a larger study.

Another Option Care study[*]Cheung K, Rout T, Banerjee U, et al. A Retrospective Evaluation of the Frequency of Vancomycin Monitoring and its Effects on Home Infusion Patients. Poster presented at the National Home Infusion Association (NHIA) Annual Conference; March 9-13, 2019, Orlando, Fla. being presented at NHIA compared results associated with frequency of therapeutic drug monitoring (TDM) among 100 patients treated with home infusion of high-dose vancomycin (a commonly prescribed antibiotic), half of whom were monitored weekly and half twice weekly. Researchers detected a potential trend that major events such as emergency department visits or hospital admissions were less prevalent among patients 55 and older who received high-dose vancomycin with twice-weekly TDM.

关于 Option Care

Option Care Enterprises, Inc. (Option Care) is the nation’s leading and most trusted provider of home and alternate site infusion services. Holding accreditations from industry quality organizations ACHC, PCAB, ASHP and URAC,[*]Accreditation Commission for Health Care (ACHC), Pharmacy Compounding Accreditation Board (PCAB), American Society of Health-System Pharmacists (ASHP) and URAC the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature infusion services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.